In a new, four month, controlled registry study undertaken by Italian researchers, Indena says that its Enovita proprietary standardised grape seed extract, which is said to be rich in proanthocyanidins, has shown efficacy in maintaining healthy blood pressure when associated with nondrug intervention (diet and lifestyle modification).
The study involved 119 otherwise healthy pre- and mildly hypertensive subjects, and lasted four months. Inclusion criteria were general good health and borderline hypertension, defined as pre-hypertension (120-139 mm Hg / 80-89 mm Hg) and stage 1 hypertension (140-159 mm Hg / 90-99 mm Hg).
The nondrug intervention included diet (reduction in salt, alcohol and caffeinated drinks) and lifestyle (regular exercise, improvement of sleep time, relaxation and reduction of smoking). No other nutritional elements, vitamins or drugs were used in the observation period. No side effects were reported during the execution of the study, and formulation tolerability was said to be very good.
The subjects were divided into three groups, similar in terms of age and all objective parameters were evaluated – namely, systolic and diastolic blood pressure, microcirculatory status (LDF), heart rate and plasma oxidative status. Group 1 (37 subjects) and Group 2 (35 subjects) complemented the management plan with Enovita at two different daily dosages (300 mg/day for Group 1 and 150 mg/day for Group 2), while in subjects from Group 3 (47 subjects) only the management plan was implemented, serving as the control. The endpoints of the study were evaluated monthly, in order to assess the kinetic of development of any beneficial effect. The blood pressure normalisation was found to be significantly higher in the Enovita supplementation groups starting from the 4th week of supplementation.
“Taken together, our data suggest that GSPs, at least in the profile associated to Indena’s Enovita, are worth considering to complement dietary and lifestyle changes associated to the maintenance of a healthy blood pressure status, with beneficial cardiovascular effect,” said Dr. Gianni Belcaro, of the Department of Biomedical Science, Gabriele D’Annunzio University Chieti-Pescara, head of the study.
The study involved 119 otherwise healthy pre- and mildly hypertensive subjects, and lasted four months. Inclusion criteria were general good health and borderline hypertension, defined as pre-hypertension (120-139 mm Hg / 80-89 mm Hg) and stage 1 hypertension (140-159 mm Hg / 90-99 mm Hg).
The nondrug intervention included diet (reduction in salt, alcohol and caffeinated drinks) and lifestyle (regular exercise, improvement of sleep time, relaxation and reduction of smoking). No other nutritional elements, vitamins or drugs were used in the observation period. No side effects were reported during the execution of the study, and formulation tolerability was said to be very good.
The subjects were divided into three groups, similar in terms of age and all objective parameters were evaluated – namely, systolic and diastolic blood pressure, microcirculatory status (LDF), heart rate and plasma oxidative status. Group 1 (37 subjects) and Group 2 (35 subjects) complemented the management plan with Enovita at two different daily dosages (300 mg/day for Group 1 and 150 mg/day for Group 2), while in subjects from Group 3 (47 subjects) only the management plan was implemented, serving as the control. The endpoints of the study were evaluated monthly, in order to assess the kinetic of development of any beneficial effect. The blood pressure normalisation was found to be significantly higher in the Enovita supplementation groups starting from the 4th week of supplementation.
“Taken together, our data suggest that GSPs, at least in the profile associated to Indena’s Enovita, are worth considering to complement dietary and lifestyle changes associated to the maintenance of a healthy blood pressure status, with beneficial cardiovascular effect,” said Dr. Gianni Belcaro, of the Department of Biomedical Science, Gabriele D’Annunzio University Chieti-Pescara, head of the study.
